Teva’s Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug’s potential in treating IBD. Latest Ratings for TEVA Date Firm Action From To Feb 2022 Barclays Maintains Equal-Weight Jan 2022 Argus Research Downgrades Buy Hold Oct 2021 Raymond James Downgrades Outperform Market Perform View More Analyst Ratings for TEVA View the…

Read More

Chemours, Tronox And Westlake Will See Earnings Rebound In Chemical Sector Amid TiO2 Recovery And Margin Expansion: Analyst

Truist Securities analyst initiates coverage on chemicals stocks before earnings release. Companies include Chemours, Tronox, Minerals Tech, and Westlake. Latest Ratings for CC Date Firm Action From To Feb 2022 RBC Capital Maintains Outperform Feb 2022 JP Morgan Maintains Neutral Jan 2022 UBS Maintains Neutral View More Analyst Ratings for CC View the Latest Analyst…

Read More